JP2020505468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505468A5 JP2020505468A5 JP2019561389A JP2019561389A JP2020505468A5 JP 2020505468 A5 JP2020505468 A5 JP 2020505468A5 JP 2019561389 A JP2019561389 A JP 2019561389A JP 2019561389 A JP2019561389 A JP 2019561389A JP 2020505468 A5 JP2020505468 A5 JP 2020505468A5
- Authority
- JP
- Japan
- Prior art keywords
- branched
- linear
- alkyl
- halide
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 64
- 150000004820 halides Chemical class 0.000 claims description 47
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 229920006395 saturated elastomer Polymers 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- -1 heterocyclyl compound Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 102000008122 Casein Kinase I Human genes 0.000 description 4
- 108010049812 Casein Kinase I Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 0 CC(CC1)(CCC1(*)Nc1ccc(*)c(-c2c(*)[n](*)nc2*)n1)N(*)* Chemical compound CC(CC1)(CCC1(*)Nc1ccc(*)c(-c2c(*)[n](*)nc2*)n1)N(*)* 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000045959 Interleukin-1 Receptor-Like 1 Human genes 0.000 description 2
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 208000020158 breast diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453192P | 2017-02-01 | 2017-02-01 | |
| US62/453,192 | 2017-02-01 | ||
| PCT/IL2018/050100 WO2018142393A1 (en) | 2017-02-01 | 2018-01-30 | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505468A JP2020505468A (ja) | 2020-02-20 |
| JP2020505468A5 true JP2020505468A5 (enExample) | 2021-03-18 |
| JP7142646B2 JP7142646B2 (ja) | 2022-09-27 |
Family
ID=61198874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019561389A Active JP7142646B2 (ja) | 2017-02-01 | 2018-01-30 | がんを治療するためのｃｋ１及び／又はｉｒａｋ１インヒビターとしてのｎ１－（４－（５－（シクロプロピルメチル）－１－メチル－１ｈ－ピラゾール－４－イル）ピリジン－２－イル）シクロヘキサン－１，４－ジアミン誘導体及び関連化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11072599B2 (enExample) |
| EP (1) | EP3577108B1 (enExample) |
| JP (1) | JP7142646B2 (enExample) |
| KR (1) | KR20190115017A (enExample) |
| CN (1) | CN110475771B (enExample) |
| AU (1) | AU2018215809B2 (enExample) |
| CA (1) | CA3052247A1 (enExample) |
| ES (1) | ES2902885T3 (enExample) |
| IL (1) | IL268128B2 (enExample) |
| MX (1) | MX394556B (enExample) |
| NZ (1) | NZ755447A (enExample) |
| RU (1) | RU2761457C2 (enExample) |
| SG (1) | SG11201906681PA (enExample) |
| TW (1) | TW201837027A (enExample) |
| WO (1) | WO2018142393A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3331877T3 (da) * | 2015-08-04 | 2022-01-03 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Pyrazolpyrimidinderivat og anvendelser deraf |
| US20200383984A1 (en) * | 2018-02-08 | 2020-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| CN114127058B (zh) * | 2019-07-04 | 2024-06-25 | 深圳国顺康医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| CN116490503A (zh) * | 2020-09-17 | 2023-07-25 | 詹森药业有限公司 | 酪蛋白激酶1δ调节剂 |
| US20240239774A1 (en) * | 2021-04-28 | 2024-07-18 | Cornell University | Soluble adenylyl cyclase (sac) inhibitors and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| MX358682B (es) | 2010-07-13 | 2018-08-31 | Hoffmann La Roche | Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| RU2674017C2 (ru) | 2011-11-04 | 2018-12-04 | ДЖАСКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Аминопиримидиновые ингибиторы киназ |
| CN106232122A (zh) | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| HUE047586T2 (hu) * | 2014-11-20 | 2020-04-28 | Merck Patent Gmbh | Heteroaril vegyületek mint IRAK inhibitorok és alkalmazásaik |
| CN113350352B (zh) * | 2015-03-23 | 2024-09-10 | 天莅生物科技私人有限公司 | 呼吸性疾病的治疗 |
| DK3331877T3 (da) * | 2015-08-04 | 2022-01-03 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Pyrazolpyrimidinderivat og anvendelser deraf |
-
2018
- 2018-01-30 JP JP2019561389A patent/JP7142646B2/ja active Active
- 2018-01-30 SG SG11201906681PA patent/SG11201906681PA/en unknown
- 2018-01-30 US US16/482,199 patent/US11072599B2/en active Active
- 2018-01-30 CA CA3052247A patent/CA3052247A1/en active Pending
- 2018-01-30 NZ NZ755447A patent/NZ755447A/en unknown
- 2018-01-30 KR KR1020197025024A patent/KR20190115017A/ko not_active Ceased
- 2018-01-30 IL IL268128A patent/IL268128B2/en unknown
- 2018-01-30 ES ES18705024T patent/ES2902885T3/es active Active
- 2018-01-30 CN CN201880022829.8A patent/CN110475771B/zh not_active Expired - Fee Related
- 2018-01-30 EP EP18705024.0A patent/EP3577108B1/en active Active
- 2018-01-30 WO PCT/IL2018/050100 patent/WO2018142393A1/en not_active Ceased
- 2018-01-30 TW TW107103255A patent/TW201837027A/zh unknown
- 2018-01-30 RU RU2019127038A patent/RU2761457C2/ru active
- 2018-01-30 AU AU2018215809A patent/AU2018215809B2/en not_active Ceased
- 2018-01-30 MX MX2019009083A patent/MX394556B/es unknown
-
2021
- 2021-07-26 US US17/384,922 patent/US11999721B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505468A5 (enExample) | ||
| RU2018107668A (ru) | Пиразолпиримидиновое производное и его применение | |
| RU2475484C2 (ru) | Полициклические производные индазола и их применение в качестве ингибиторов erk для лечения рака | |
| JP2018525441A5 (enExample) | ||
| IL268030B2 (en) | Bicyclic compounds as allosteric shp2 inhibitors | |
| JP2020503303A5 (enExample) | ||
| IL286846B2 (en) | Camptothecin derivatives | |
| IL278381B2 (en) | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer | |
| JP2020506951A5 (enExample) | ||
| JP2015509110A5 (enExample) | ||
| RU2019127038A (ru) | N1-(4-(5-(циклопропилметил)-1-метил-1h-пиразол-4-ил)пиридин-2-ил)циклогексан-1,4-диаминовые производные и родственные соединения в качестве ингибиторов сk1 и/или irak1 для лечения рака | |
| JP2018138577A5 (enExample) | ||
| RU2015118145A (ru) | Замещенные бензольные соединения | |
| JP2016503799A5 (enExample) | ||
| JP2020530838A5 (enExample) | ||
| RU2019122598A (ru) | Циклические динуклеотидные агонисты sting для лечения рака | |
| JP2019518766A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| CN101142198A (zh) | 用于治疗疾病的异唑坎布雷它斯丁衍生物 | |
| JP2017530984A5 (enExample) | ||
| JP2015517574A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2017517565A5 (enExample) | ||
| JP2017530983A5 (enExample) |